BR9816049A - (+) - alpha- (2,3-dimethoxyphenyl) -1- [2- (4-fluorophenyl) ethyl] -4-pi peridinomethanol esters and their use as prodrugs of the 5ht2a mdl receptor antagonist 110,907 - Google Patents
(+) - alpha- (2,3-dimethoxyphenyl) -1- [2- (4-fluorophenyl) ethyl] -4-pi peridinomethanol esters and their use as prodrugs of the 5ht2a mdl receptor antagonist 110,907Info
- Publication number
- BR9816049A BR9816049A BR9816049-4A BR9816049A BR9816049A BR 9816049 A BR9816049 A BR 9816049A BR 9816049 A BR9816049 A BR 9816049A BR 9816049 A BR9816049 A BR 9816049A
- Authority
- BR
- Brazil
- Prior art keywords
- esters
- alpha
- peridinomethanol
- 5ht2a
- dimethoxyphenyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
- C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Addiction (AREA)
- Epidemiology (AREA)
- Hydrogenated Pyridines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Patente de Invenção: <B>"éSTERES DE (+)-ALFA-(2,3-DIMETOXIFENIL)-1-[2-(4-FLUOROFENIL)ETIL]-4-PI PERIDINOMETANOL E SEU USO COMO PRó-DROGAS DO ANTAGONISTA DE RECEPTOR 5HT2A MDL 110.907"<D>. A presente invenção é direcionada a ésteres de (+)-alfa-(2,3-dimetoxifenil)-1-[2-(4-fluorofenil)etil]-4-piperidino metanol, de fórmula (I) onde R é C~ 4-20~ alquila, formulações farmacêuticas, métodos de fabricação e métodos de uso destes ésteres. Estes compostos antagonizamos efeitos de serotonina no receptor 5HT~ 2A~ e são úteis no tratamento de várias condições tais como, por exemplo, psicoses tais como esquizofrenia.Invention Patent: <B> "(+) - ALPHA- (2,3-DIMETOXYphenyl) -1- [2- (4-FLUOROFENYL) ETHERS] -4-PI PERIDINOMETHANOL ESTERS AND THEIR USE AS ANTAGONIST PRO-DRUGS RECEIVER 5HT2A CDM 110.907 "<D>. The present invention is directed to esters of (+) - alpha- (2,3-dimethoxyphenyl) -1- [2- (4-fluorophenyl) ethyl] -4-piperidine methanol, of formula (I) where R is C ~ 4-20 ~ alkyl, pharmaceutical formulations, manufacturing methods and methods of using these esters. These compounds antagonize serotonin effects at the 5HT ~ 2A ~ receptor and are useful in the treatment of various conditions such as, for example, psychoses such as schizophrenia.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/US1998/021608 WO2000021930A1 (en) | 1998-10-14 | 1998-10-14 | Esters of (+)-alpha-( 2,3- dimethoxyphenyl) -1-[2-(4- fluorophenyl) ethyl]-4- piperidinemethanol and their use as prodrugs of the 5ht2a receptor antagonist mdl 110,907 |
Publications (1)
Publication Number | Publication Date |
---|---|
BR9816049A true BR9816049A (en) | 2001-07-03 |
Family
ID=22268079
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR9816049-4A BR9816049A (en) | 1998-10-14 | 1998-10-14 | (+) - alpha- (2,3-dimethoxyphenyl) -1- [2- (4-fluorophenyl) ethyl] -4-pi peridinomethanol esters and their use as prodrugs of the 5ht2a mdl receptor antagonist 110,907 |
Country Status (21)
Country | Link |
---|---|
EP (1) | EP1121345A1 (en) |
JP (1) | JP2002527422A (en) |
KR (1) | KR100515429B1 (en) |
CN (1) | CN1160333C (en) |
AU (1) | AU1083099A (en) |
BR (1) | BR9816049A (en) |
CA (1) | CA2347469C (en) |
CZ (1) | CZ20011331A3 (en) |
EA (1) | EA003667B1 (en) |
EE (1) | EE200100219A (en) |
HK (1) | HK1039332A1 (en) |
HR (1) | HRP20010278A2 (en) |
HU (1) | HUP0200517A3 (en) |
IL (2) | IL142479A0 (en) |
NO (1) | NO320417B1 (en) |
NZ (1) | NZ510631A (en) |
PL (1) | PL193306B1 (en) |
SK (1) | SK5082001A3 (en) |
TR (1) | TR200101047T2 (en) |
UA (1) | UA57859C2 (en) |
WO (1) | WO2000021930A1 (en) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020099076A1 (en) * | 2000-05-25 | 2002-07-25 | Richard Scheyer D. | Use of (+)-a-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl) ethyl]-4-piperidinemethanol or its prodrug in the treatment of symptoms of dementia and dopamine induced psychosis |
CN102241667B (en) * | 2010-05-14 | 2013-10-23 | 中国人民解放军军事医学科学院毒物药物研究所 | 1-[(4-hydroxypiperidine-4-yl) methyl] pyridine-2(1H)-one derivatives, preparation method and use thereof |
CN106892897A (en) * | 2015-12-21 | 2017-06-27 | 上海科胜药物研发有限公司 | A kind of hydroxyl piperazine pyrrone free alkali novel crystal forms and preparation method thereof |
CN106928187A (en) * | 2015-12-31 | 2017-07-07 | 上海奥博生物医药技术有限公司 | A kind of hydrochloric acid hydroxyl piperazine pyrrone novel crystal forms and preparation method thereof |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU652759B2 (en) * | 1990-06-01 | 1994-09-08 | Aventisub Ii Inc. | (+)-alpha-(2,3-dimethoxyphenyl)-1-(2-(4-fluorophenyl)ethyl)- 4-piperidinemethanol |
-
1998
- 1998-10-14 JP JP2000575839A patent/JP2002527422A/en active Pending
- 1998-10-14 CN CNB988142740A patent/CN1160333C/en not_active Expired - Fee Related
- 1998-10-14 BR BR9816049-4A patent/BR9816049A/en not_active Application Discontinuation
- 1998-10-14 AU AU10830/99A patent/AU1083099A/en not_active Abandoned
- 1998-10-14 EA EA200100361A patent/EA003667B1/en not_active IP Right Cessation
- 1998-10-14 KR KR10-2001-7004703A patent/KR100515429B1/en not_active IP Right Cessation
- 1998-10-14 NZ NZ510631A patent/NZ510631A/en active IP Right Revival
- 1998-10-14 CA CA002347469A patent/CA2347469C/en not_active Expired - Fee Related
- 1998-10-14 TR TR2001/01047T patent/TR200101047T2/en unknown
- 1998-10-14 HU HU0200517A patent/HUP0200517A3/en unknown
- 1998-10-14 EE EEP200100219A patent/EE200100219A/en unknown
- 1998-10-14 CZ CZ20011331A patent/CZ20011331A3/en unknown
- 1998-10-14 SK SK508-2001A patent/SK5082001A3/en not_active Application Discontinuation
- 1998-10-14 PL PL347318A patent/PL193306B1/en not_active IP Right Cessation
- 1998-10-14 EP EP98953458A patent/EP1121345A1/en not_active Withdrawn
- 1998-10-14 IL IL14247998A patent/IL142479A0/en active IP Right Grant
- 1998-10-14 UA UA2001042522A patent/UA57859C2/en unknown
- 1998-10-14 WO PCT/US1998/021608 patent/WO2000021930A1/en active IP Right Grant
-
2001
- 2001-04-05 IL IL142479A patent/IL142479A/en not_active IP Right Cessation
- 2001-04-09 NO NO20011805A patent/NO320417B1/en not_active IP Right Cessation
- 2001-04-12 HR HR20010278A patent/HRP20010278A2/en not_active Application Discontinuation
-
2002
- 2002-02-05 HK HK02100869A patent/HK1039332A1/en not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
PL193306B1 (en) | 2007-01-31 |
SK5082001A3 (en) | 2001-11-06 |
EE200100219A (en) | 2002-08-15 |
NZ510631A (en) | 2003-07-25 |
NO20011805L (en) | 2001-06-08 |
HUP0200517A3 (en) | 2002-12-28 |
NO320417B1 (en) | 2005-12-05 |
CN1160333C (en) | 2004-08-04 |
CN1314887A (en) | 2001-09-26 |
KR20010106517A (en) | 2001-11-29 |
PL347318A1 (en) | 2002-03-25 |
WO2000021930A1 (en) | 2000-04-20 |
CZ20011331A3 (en) | 2001-08-15 |
EA003667B1 (en) | 2003-08-28 |
HRP20010278A2 (en) | 2002-06-30 |
JP2002527422A (en) | 2002-08-27 |
AU1083099A (en) | 2000-05-01 |
CA2347469A1 (en) | 2000-04-20 |
HUP0200517A2 (en) | 2002-06-29 |
UA57859C2 (en) | 2003-07-15 |
CA2347469C (en) | 2006-02-28 |
IL142479A (en) | 2006-06-11 |
HK1039332A1 (en) | 2002-04-19 |
EP1121345A1 (en) | 2001-08-08 |
TR200101047T2 (en) | 2001-08-21 |
NO20011805D0 (en) | 2001-04-09 |
EA200100361A1 (en) | 2001-10-22 |
IL142479A0 (en) | 2002-03-10 |
KR100515429B1 (en) | 2005-09-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2009006018A (en) | Quinuclidinol derivatives as muscarinic receptor antagonists. | |
MY124390A (en) | Substituted bicyclic derivatives useful as anticancer agents | |
CO5180642A1 (en) | PIPERIDINE REPLACED COMPOUNDS, PROCESSES FOR THEIR PREPARATION, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE | |
ES2160525A1 (en) | 4-aroyl-piperidin-ccr-3 receptor antagonists iii | |
NO20000572L (en) | Indole derivatives as MCP-1 receptor antagonists | |
KR20050085991A (en) | Compounds exhibiting thrombopoietin receptor agonism | |
MY130803A (en) | New quinuclidine amide derivatives | |
ES2158813A1 (en) | Piperidine ccr-3 receptor antagonists | |
UA83091C2 (en) | Pyrido[2,3-d]pyrimidine-2,4-diamines as pde 2 inhibitors | |
DK1159279T3 (en) | 4-Oxo-4,7-dihydro-thieno [2,3-b] pyridine-5-carboxamides as antivirals | |
NO20025641D0 (en) | Substituted 1-aminoalkyl lactams and their use as muscarinic receptor antagonists | |
PT1499590E (en) | PIPERDINE DERIVATIVES AS POTASSIUM CHANNEL BLOCKERS | |
DE602004009200D1 (en) | TETRAHYDROCHINAZOLINE DERIVATIVES AS CFR ANTAGONISTS | |
IL174678A0 (en) | Arylindenophyridines and arylindenophyrimidines and their use as adenosine a2a receptor antagonist | |
PA8495101A1 (en) | DERIVATIVES OF 13-METHYLERITROMYCIN | |
YU53100A (en) | 2-arylethyl-(piperidin-4-ylmethyl)amine derivatives as muscarinic receptor antagonists | |
PL361282A1 (en) | Substituted 1-aminoalkyl-lactams and their use as muscarinic receptor antagonists | |
ATE221064T1 (en) | CYCLIC AMIDE DERIVATIVES AS NEUROKIN A ANTAGONISTS | |
TR200101711T2 (en) | Antihistamine spiro compounds. | |
MXPA04005076A (en) | 4-piperidinyl alkylamine derivatives as muscarinic receptor antagonists. | |
BR9816049A (en) | (+) - alpha- (2,3-dimethoxyphenyl) -1- [2- (4-fluorophenyl) ethyl] -4-pi peridinomethanol esters and their use as prodrugs of the 5ht2a mdl receptor antagonist 110,907 | |
HK1053109A1 (en) | Substituted homopiperidinyl benzimidazole compounds, pharmaceutical compositions comprising the same, methods for preparing them and the use for the preparation of a medicament of them | |
MXPA05011841A (en) | Methyl indoles and methyl pyrrolopyridines as alph-1 adrenergic agonists. | |
DE60209014D1 (en) | Tricylic CRF receptor antagonists | |
BR0112957A (en) | Compound, method of treatment, use of a compound, and pharmaceutical composition |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B06G | Technical and formal requirements: other requirements [chapter 6.7 patent gazette] |
Free format text: FOI APRESENTADA ATRAVES DA PETICAO NO 40022 DE 17/08/2001 O PEDIDO DE EXAME CONTENDO UM TOTAL DE 55 REIVINDICACOES, ENTRETANTO O REQUERENTE ANEXOU UMA NOVA FOLHA 5 AO QUADRO REIVINDICATORIO, A QUAL ADICIONA UMA REIVINDICACAO AO QUADRO, PERFAZENDO UM TOTAL DE 56 REIVINDICACOES, PELO EXPOSTO, SOLICITA-SE QUE O REQUERENTE DEFINA QUAL QUADRO REIVINDICATORIO DEVE SER AXAMINADO, E QUE CASO SEJA DEFINIDO O QUE POSSUI 56 REINVIDICACOES QUE SEJA EFETUADO O PAGAMENTO DA 56O. O DEPOSITANTE DEVE TOMAR CONHECIMENTO DESTE PARECER, PODENDO MANIFESTAR-SE NO PRAZO DE 60 DIAS, CONTADOS DA DATA DA PUBLICACAO DESTE RPI. |
|
B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
B09B | Patent application refused [chapter 9.2 patent gazette] |
Free format text: INDEFERIMENTO DO PRESENTE PEDIDO, UMA VEZ QUE NAO ATENDE AOS ARTIGOS 8O E 13 DA LPI. |
|
B09B | Patent application refused [chapter 9.2 patent gazette] |
Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL. |